Request Investor Info

Investor Alert - Defence Therapeutics: Developing Immune-related Therapies for Cancer Treatment

April 19, 2023

Exciting Growth Potential for Investors in Defence Therapeutics Stocks

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles. The company's proprietary technology enables the delivery of bio drugs past intracellular barriers. The company is excited about three clinical trials scheduled to start by the end of the year, which are crucial for the company's future growth. Defence Therapeutics is seeking to license its technology to other companies and pharmaceutical companies for product enhancement.

‍

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

Latest Articles

Centurion CEO Romundt Sees Generational Opportunity in Real Estate Finance

TD Q U.S. Small-Mid-Cap Equity ETF Offers an Investment Opportunity Not Seen in a Long Time ETFs

Mission Critical: How XPhyto Therapeutics Could Revolutionize PCR Testing Cannabis

Algernon Pharmaceuticals: Investigating a Novel Therapy for Stroke Patients Using the Psychedelic Drug N,N-Dimethyltryptamine (DMT)Healthcare

Hot Companies

Aston Bay Holdings

KITS Eyecare Ltd.

You might also like

Lexaria Bioscience: Transforming GLP-1 Drug Delivery for a Growing Market

Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Sernova: Advancing the Future of Diabetes Treatment

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!